Trial · NCT00105521
Results by group24
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 24
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in Diary-Based On-Time Without Dyskinesia at Week 12 | Placebo | 1.6 | Standard Deviation 3.3 | hours/day | |
| Change From Baseline in Diary-Based On-Time Without Dyskinesia at Week 12 | Sarizotan 2 mg/Day | 1.9 | Standard Deviation 3.8 | hours/day | |
| Change From Baseline in Diary-Based On-Time Without Dyskinesia at Week 12 | Sarizotan 4 mg/Day | 1.7 | Standard Deviation 3.0 | hours/day | |
| Change From Baseline in Diary-Based On-Time Without Dyskinesia at Week 12 | Sarizotan 10 mg/Day | 1.8 | Standard Deviation 3.1 | hours/day | |
| Change From Baseline in Modified Abnormal Involuntary Movement Scale (AIMS) Score at Week 12 | Placebo | Change at Week 12: Modified AIMS at Rest | -2.7 | Standard Deviation 5.7 | units on a scale |
| Change From Baseline in Modified Abnormal Involuntary Movement Scale (AIMS) Score at Week 12 | Sarizotan 2 mg/Day | Change at Week 12: Modified AIMS at Rest | -3.0 | Standard Deviation 5.3 | units on a scale |
| Change From Baseline in Modified Abnormal Involuntary Movement Scale (AIMS) Score at Week 12 | Sarizotan 4 mg/Day | Change at Week 12: Modified AIMS at Rest | -2.7 | Standard Deviation 4.1 | units on a scale |
| Change From Baseline in Modified Abnormal Involuntary Movement Scale (AIMS) Score at Week 12 | Sarizotan 10 mg/Day | Change at Week 12: Modified AIMS at Rest | -3.7 | Standard Deviation 5.5 | units on a scale |
| Change From Baseline in Modified Abnormal Involuntary Movement Scale (AIMS) Score at Week 12 | Placebo | Change at Week 12: Modified AIMS with Activity | -3.0 | Standard Deviation 5.9 | units on a scale |
| Change From Baseline in Modified Abnormal Involuntary Movement Scale (AIMS) Score at Week 12 | Sarizotan 2 mg/Day | Change at Week 12: Modified AIMS with Activity | -3.3 | Standard Deviation 5.6 | units on a scale |
| Change From Baseline in Modified Abnormal Involuntary Movement Scale (AIMS) Score at Week 12 | Sarizotan 4 mg/Day | Change at Week 12: Modified AIMS with Activity | -3.0 | Standard Deviation 4.8 | units on a scale |
| Change From Baseline in Modified Abnormal Involuntary Movement Scale (AIMS) Score at Week 12 | Sarizotan 10 mg/Day | Change at Week 12: Modified AIMS with Activity | -3.6 | Standard Deviation 6.0 | units on a scale |
| Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Items 32 and 33 Composite Score at Week 12 | Placebo | -1.0 | Standard Deviation 1.4 | units on a scale | |
| Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Items 32 and 33 Composite Score at Week 12 | Sarizotan 2 mg/Day | -1.4 | Standard Deviation 1.6 | units on a scale | |
| Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Items 32 and 33 Composite Score at Week 12 | Sarizotan 4 mg/Day | -1.1 | Standard Deviation 1.4 | units on a scale | |
| Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Items 32 and 33 Composite Score at Week 12 | Sarizotan 10 mg/Day | -1.3 | Standard Deviation 1.3 | units on a scale | |
| Change From Baseline in UPDRS Part III Total Score at Week 12 | Placebo | Change at Week 12: UPDRS Part III On-Time | 0.3 | Standard Deviation 6.8 | units on a scale |
| Change From Baseline in UPDRS Part III Total Score at Week 12 | Sarizotan 2 mg/Day | Change at Week 12: UPDRS Part III On-Time | -0.1 | Standard Deviation 6.4 | units on a scale |
| Change From Baseline in UPDRS Part III Total Score at Week 12 | Sarizotan 4 mg/Day | Change at Week 12: UPDRS Part III On-Time | -0.1 | Standard Deviation 6.8 | units on a scale |
| Change From Baseline in UPDRS Part III Total Score at Week 12 | Sarizotan 10 mg/Day | Change at Week 12: UPDRS Part III On-Time | -0.8 | Standard Deviation 7.1 | units on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00105521/results